INTRODUCTION
============

Sepsis is an important global health concern. A recent systematic review of study data from high-income countries yielded estimates of 31.5 million sepsis cases and 5.3 million deaths worldwide each year \[[@b1-acc-2019-00514]\]. In addition, many patients who survive sepsis subsequently suffer from substantial cognitive impairment and functional disability \[[@b2-acc-2019-00514]\]. To reduce the burden of sepsis, the World Health Organization has recommended implementing epidemiologic surveillance systems and monitoring the incidence and outcomes from sepsis, together with concerted efforts to reduce antimicrobial resistance \[[@b3-acc-2019-00514]\]. Given the incidence, etiology, treatment and outcomes of sepsis vary by geographical region and change over time, national data must be continually updated to guide each country's healthcare policy and to allocate appropriate healthcare resources to manage sepsis \[[@b4-acc-2019-00514]-[@b6-acc-2019-00514]\].

The mortality rates associated with sepsis have increased progressively in Korea \[[@b7-acc-2019-00514]\]. But domestic epidemiologic data, especially regarding sepsis cases that are recognized outside the intensive care unit (ICU) remain limited. This study aimed to investigate the incidence, characteristics, treatment and outcomes of sepsis in Korea.

MATERIALS AND METHODS
=====================

Study Design and Population
---------------------------

This was a nationwide multicenter retrospective cohort study conducted by the Korean Sepsis Alliance. Nineteen tertiary or university-affiliated hospitals in Korea agreed to participate in the study. The steering committee developed the study protocol, periodically reviewed the progress, and provided overall supervision of the study. The present study was approved by the Institutional Review Boards of each participating hospital, and the requirement for informed consent was waived because of the non-interventional observational nature of the study.

We screened all consecutive patients who presented to the emergency department (ED) in one of the participating hospitals during a 1-month period (from January 1 through January 31, 2018) for eligibility. Patients who were over 19 years of age and had sepsis as defined by clinical criteria from the third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) were included in the study and followed up until death or hospital discharge. We considered sepsis to be the diagnosis if the patient satisfied the following two conditions: (1) a probable or confirmed diagnosis of infection, and (2) an acute change in total Sequential Organ Failure Assessment (SOFA) score of 2 or more consequent to the infection \[[@b8-acc-2019-00514]\]. The baseline SOFA score was assumed to be zero in patients not known to have pre-existing organ dysfunction.

Data Collection
---------------

Trained study coordinators in each participating center used the hospital records for each patient to prepare a standardized Excel spreadsheet-based case report form. The following information was collected retrospectively: (1) demographic data, including age, sex, comorbidities, SOFA score, physiological and laboratory measurements at the time of ED visit; (2) infection data, including source and type of infection, and presence of multi-drug resistance (MDR) pathogens in the case of culture-positive-infected patients; (3) treatment data, including choice and appropriateness of empiric therapy, implementation of nonsurgical or surgical source control, implementation of the 1-hour Surviving Sepsis Campaign bundle, use of adjunctive steroids, and decisions regarding limitation of life-sustaining treatments during the hospitalization; and (4) clinical outcomes, including in-hospital death and discharge destination for patients who survived to discharge. For patients admitted to the ICU for sepsis, data regarding SOFA scores at ICU admission and at the first 48 hours after ICU admission, resource use and medical events during ICU stay, and need for organ support treatment at the time of ICU discharge were also collected. All participating centers were asked to complete data entry and email the data to the coordinating center at the Samsung Medical Center, where the quality of data were assessed for completeness and logical errors.

Definitions
-----------

Infection was defined as the presence of a clinical or radiological infectious focus, or both, plus the administration of antibiotics, and was classified into one of three categories: (1) microbiologically documented infection (infection with pathogen identification), (2) clinically documented infection (infection without causative pathogen identification), and (3) possible infection (all other situations). We also divided the infections into community-acquired infection, which was present upon admission or developed within 48 hours of hospital admission, and hospital-acquired infection, which occurred \>48 hours after hospital admission. Cultured pathogens were defined as the presence of any etiologic microorganism recovered from cultures collected within 2 days before and 2 days after admission. MDR was defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories \[[@b9-acc-2019-00514]\]. Initial antimicrobial therapy begun in the absence of definitive microbiologic pathogen identification was considered an empiric therapy, and the appropriateness of empiric therapy was determined according to the results of the drug susceptibility test or the guideline recommendations \[[@b10-acc-2019-00514]\].

Septic shock was characterized by persistent arterial hypotension requiring vasopressors to maintain mean arterial pressure ≥65 mmHg and a serum lactate level \>2 mmol/L despite adequate volume resuscitation \[[@b8-acc-2019-00514]\]. The 1-hour Surviving Sepsis Campaign bundle consisted of the following elements: measure lactate level, obtain blood cultures prior to administration of antibiotics, administer broad spectrum antibiotics, begin rapid administration of 30 ml/kg of intravenous crystalloid fluid for hypotension or lactate level ≥4 mmol/L, apply vasopressors to maintain a mean arterial pressure ≥65 mmHg, and remeasure lactate level if initial lactate is \>2 mmol/L \[[@b11-acc-2019-00514]\].

Statistical Analysis
--------------------

The data were summarized using descriptive statistics: median and interquartile range (IQR; 25th and 75th percentiles) were calculated for continuous variables, while categorical variables were summarized as numbers and percentages. In order to assess differences between subgroups, data were compared using the Mann-Whitney U-test for continuous variables and the chi-square or Fisher's exact test for categorical variables, when applicable. For all analyses, a two-tailed test with a P-value less than 0.05 was considered statistically significant. Statistical analyses were performed using STATA ver. 14.0 (Stata Corp., College Station, TX, USA).

RESULTS
=======

Patient Characteristics
-----------------------

During the 1-month study period, 64,021 patients visited the EDs of the participating hospitals: 977 (1.5%) were identified as having sepsis through the medical records review and were included in the study. Among these, 357 patients (36.5%) met the clinical criteria for septic shock. Patient characteristics at the time of the ED visit are summarized in [Table 1](#t1-acc-2019-00514){ref-type="table"}. The median age was 75 years (IQR, 64--81 years) and 57.2% were male. Diabetes (29.1%), cardiovascular diseases (27.6%), and solid malignant tumors (26.4%) were the most frequent comorbidities. The median SOFA score was 5 (IQR, 3--7).

The comorbidities of patients with sepsis were similar to those of patients with shock, except for chronic pulmonary diseases ([Table 1](#t1-acc-2019-00514){ref-type="table"}). The SOFA score was higher in patients with septic shock (4 vs. 8, P\<0.001). The scores of each organ system were also different according to the presence of septic shock and the site of infection. In addition, myocardial depression was identified in 40 (46.5%) of 88 sepsis patients and 48 (62.3%) of 78 septic shock patients who underwent echocardiography (P=0.043), and the proportion of severe left ventricular systolic dysfunction tended to be higher in patients with septic shock (35.1% vs. 56.3%, P=0.053).

Characteristics of Infection
----------------------------

Most of the infections were community-acquired infections (80.9%) ([Table 2](#t2-acc-2019-00514){ref-type="table"}). The most common primary site of infection was the respiratory system (61.8%), followed by the abdominal cavity (16.5%) and genitourinary system (12.5%). Although respiratory system infections were the most common cause of both sepsis and septic shock, the percentages of patients with respiratory system infections (54.1% vs. 66.3%, P\<0.001) were lower and intra-abdominal infections (21.9% vs. 13.4%, P\<0.001) were higher in patients with septic shock than in patients without shock.

Microbiologic pathogens were identified in 444 patients (45.5%) and bacteremia developed in 186 (42.3%) of these patients. Infection due to MDR pathogens occurred in 175 (39.4%) of patients with microbiologically documented infection. *Enterobacteriaceae* accounted for about half of the MDR pathogens, and *Staphylococcus aureus* was the next most common (21.1%). Pathogens were more frequently identified (52.1% vs. 41.6%, P=0.002), and the percentages of patients with bacteremia (54.5% vs. 35.2%, P\<0.001) and MDR pathogens (21.1% vs. 15.8%, P=0.039) were greater in patients with septic shock than in sepsis patients without shock.

Treatment Characteristics
-------------------------

Empiric combination therapy was used in a total of 484 patients (50.5%) ([Table 3](#t3-acc-2019-00514){ref-type="table"}). Beta-lactam antibiotics (87.5%) and fluoroquinolones (30.8%) were frequently chosen for empiric therapy. The percentages of patients administered glycopeptides (13.5% vs. 6.3%, P\<0.001) and carbapenem (13.0% vs. 4.5%, P\<0.001) were significantly greater in patients with septic shock than in patients without shock. The selection of empiric antibiotic regimen was appropriate in 68.6% of patients. The appropriateness of empiric antibiotic selection was significantly lower in infections by MDR pathogen than in infections by non-MDR pathogen (58.1% vs. 76.0%, P\<0.001) ([Figure 1](#f1-acc-2019-00514){ref-type="fig"}). In infections by MDR pathogen, the appropriateness of empiric antibiotic selection was observed in 62.2% for *Staphylococcus aureus*, 58.3% for *Enterococcus* species, 59.3% for *Enterobacteriaceae*, 57.9% for *Pseudomonas aeruginosa* and 40.0% for *Acinetobacter* species (P=0.810). Nonsurgical source control measures were implemented in 132 patients (13.5%), including intravascular or other catheter removal in 35 cases and drainage catheter insertion of 86 cases, and surgical source control was performed in 20 patients (2.1%).

In terms of compliance rates for the 1-hour sepsis bundle ([Figure 2](#f2-acc-2019-00514){ref-type="fig"}), lactate was measured in 80.5% of patients, and it was remeasured in 254 (67.0%) of the 379 patients with initial lactate \>2 mmol/L. Blood cultures were obtained within 1 hour in 91.8% of patients, but antibiotics were administered to only 69.7% of patients in the same interval. Intravenous fluid administration and vasopressor infusion were performed in 38.9% and 35.0% of the patients, respectively. Compliance with survival bundle components was significantly greater in patients with septic shock than patients without shock, except with respect to obtaining blood cultures.

A total of 294 patients (33.9%) were admitted to an intensive care unit, and data regarding treatment during the ICU stay were available for 286 of them: 182 (63.9%) and 70 (24.6%) patients received mechanical ventilation and renal replacement therapy during ICU stay, respectively. Extracorporeal membrane oxygenation for circulatory support was performed in 12 patients (4.2%). There was no significant difference in the need for organ support treatment in patients with and without shock. However, patients with septic shock were more often treated with hemoperfusion (10.7% vs. 3.5%, P=0.025).

Clinical Outcomes
-----------------

Overall, 267 patients (27.5%) died in the hospital, and hospital mortality was significantly greater in patients with septic shock than in patients without shock (43.2% vs. 18.5%, P\<0.001). Patients who died in the hospital were older and had a higher proportion of solid malignant tumor than survivors ([Table 4](#t4-acc-2019-00514){ref-type="table"}). In addition, non-survivors were more frequently associated with organ dysfunction at the time of visit to the ED and respiratory tract infection. However, there was no significant difference in the proportion of MDR pathogen, appropriateness of initial antibiotics, and source control measures. In a multivariable analysis, age, initial SOFA scores, solid or hematological malignancies, and site of infection were significant prognostic predictors for hospital mortality ([Table 5](#t5-acc-2019-00514){ref-type="table"}).

Of the patients who survived to discharge from hospital, 61.5% were discharged to home and 38.6% were transferred to hospitals or facilities ([Table 6](#t6-acc-2019-00514){ref-type="table"}). Most of the referral cases were transferred to step-down care. Patients with septic shock were more likely to be referred than sepsis patients without shock (48.3% vs. 34.7%, P=0.002). Patients with septic shock had more frequent limitation of life--sustaining treatments (52.0% vs. 23.6%, P\<0.001).

DISCUSSION
==========

In the present study, we described the clinical and microbiological characteristics and outcomes of patients with sepsis who visited an ED in Korea. We found that sepsis accounted for 1.5% (15.2/1,000 patients) of the population of adult patients visiting the ED during a 1-month period, and 36.5% of the sepsis patients presented with septic shock. The reported incidence of sepsis varies widely in different studies \[[@b12-acc-2019-00514]\], although direct comparison is difficult because of differences in screening methods and criteria for defining sepsis between studies. Our study showed comparable results when compared with reported incidence of severe sepsis (by Sepsis-2 criteria) or sepsis (by Sepsis-3 criteria) from neighboring countries or high-income countries. Recent observational studies from East Asian countries demonstrated an incidence of 0.4%--1.2% or 461--639 cases/100,000 person-years, and Fleischmann et al. \[[@b1-acc-2019-00514]\] estimated the worldwide incidence of sepsis to be 437 cases per 100,000 person-years \[[@b13-acc-2019-00514],[@b14-acc-2019-00514]\].

The mortality rate was also similar to that reported in studies of sepsis patients with organ dysfunction \[[@b1-acc-2019-00514]\]. In our study, patients with sepsis showed a high mortality rate: one quarter of sepsis patients---and more than 40% of patients with septic shock---died in the hospital. The patients in our cohort were older than sepsis patients in studies from Western countries, reflecting the rapidly aging Korean population. Increasing age has been suggested to be an independent factor associated with poor outcomes in sepsis \[[@b15-acc-2019-00514],[@b16-acc-2019-00514]\]. Hospital mortality among the patients in our study was consistent with reported mortality for sepsis patients, but approximately 40% of our patients were transferred to step-down care facilities after recovery from sepsis. The high rates of underlying comorbidities and limitation of life-sustaining treatment in elderly patients may have influenced these outcomes. A recent study from Japan also showed that elderly patients with various comorbidities were major population of patients receiving ICU treatment due to sepsis and only one-third of sepsis patients were discharged home \[[@b16-acc-2019-00514]\].

The respiratory system was the most common route of infection, similar to other studies \[[@b15-acc-2019-00514],[@b17-acc-2019-00514],[@b18-acc-2019-00514]\]. In addition, the proportion of infections of respiratory system in our study was greater than in other studies, including that from another study from Korea \[[@b19-acc-2019-00514]\]. Increasing age is considered a risk factor for community-acquired pneumonia in high-income countries, and death rates due to pneumonia in elderly patients have increased over the past 30 years in Korea, in association with socioeconomic improvements and aging of the population \[[@b20-acc-2019-00514]\]. In addition to the relatively older population, having collected patient data during the winter may be also a reason for the higher proportion of respiratory system infections in our study \[[@b21-acc-2019-00514]\]. Among the infections where the causative microorganism was identified as the cause of sepsis, 38% were associated with MDR pathogens, which was greater than in the Extended Prevalence of Infection in Intensive Care (EPIC II) study describing the prevalence of infections in ICUs in Western countries \[[@b6-acc-2019-00514]\]. MDR is associated with initially inappropriate antibiotic therapy, and it results in an increased risk of in-hospital mortality \[[@b22-acc-2019-00514]\]. While consistent with prior studies, a recent retrospective observational study from India shows that higher odds for mortality of MDR infection in the non-ICU population, but this relationship was not statistically significant in the ICU population \[[@b23-acc-2019-00514]\]. In our study, the inappropriate antibiotic therapy in infections associated with MDR pathogens was high, but did not affect mortality. This result might be attributed to the development of organ failure at the time of presentation, although there was no difference in the initial SOFA scores between the two groups.

We characterized the patterns of empiric antibiotic therapy and the 1-hour sepsis bundle approach in clinical practice, as well as the epidemiology of sepsis, and identified considerable differences in the initial resuscitation and treatment of sepsis depending on presence of shock. In patients with septic shock, the use of glycopeptides and carbapenem and administration of antibiotics and measurement of lactate within one hour were significantly more frequent than in sepsis patients without shock. This difference might reflect the lack of compliance with the international guidelines for management of sepsis \[[@b10-acc-2019-00514]\], but could also be interpreted as a result of failure of early recognition of sepsis in patients without hemodynamic instability. The rates of fluid and vasopressor infusion were also significantly greater in patients with septic shock. However, it is difficult to distinguish whether these results were due to lower adherence to the bundle approach or to lower rates fluid or vasopressor therapy in patients without shock, because we did not assess indicators of hydration status (hypotension or lactate ≥4 mmol/L) or the use of vasopressor therapy (hypotension during or after fluid resuscitation) \[[@b11-acc-2019-00514]\].

Although our study provided information regarding the prevalence, patient and infection characteristics, and outcomes in sepsis patients diagnosed using Sepsis-3 definitions, and regarding compliance with the 1-hour sepsis bundle in Korea, there are several limitations that should be considered. First, because of the retrospective nature of the study, our findings remain prone to various biases. We used a national multicenter design to improve the generalizability of our findings, but there is a potential risk of selection bias, because only patients visiting tertiary or university-affiliated hospitals were included in the study. Next, the incidence of sepsis might have been underestimated in this study, as we did not evaluate sepsis identified on general wards or in ICUs during hospitalization, or sepsis caused by viral or fungal infections. In addition, given the incidence and characteristics of infection may vary depending on the season, we could not exclude the possibility that the incidence of sepsis might have been different if the study had been conducted during a different (non-winter) season. Finally, the causal relationship between sepsis and death could not be identified in this study. Additional prospective studies of sepsis, addressing a larger number of patients followed for a longer period of time, are needed to better define the public health and economic burden of sepsis. Further prospective and nation-wide studies should deal with evaluation for viral and fungal infection in order to comprehensively understand the microbiological characteristics and improve the appropriateness of antimicrobial use, and analysis of detailed cost and economic burden as well as clinical outcomes.

In Korea, the incidence and mortality of patients with sepsis were comparable to those reported in other high-income countries. Patients with sepsis, in addition to having a high mortality, were more commonly referred to step-down facilities rather than discharged home even after acute sepsis care. Our study found differences between the participating hospitals with regard to compliance with current recommendations for initial resuscitation and treatment of sepsis and septic shock, which suggests that knowledge of and experience with early recognition and treatment of sepsis may still be lacking. Further epidemiologic studies and development of healthcare policies aimed at improving awareness of sepsis and promoting implementation of the recommended sepsis care protocols are needed to improve the outcomes of sepsis.

KEY MESSAGES
============

▪The prevalence of sepsis in adult patients visiting an emergency department during a 1-month period in Korea was 1.5% (15.2/1,000 patients).

▪Overall in-hospital mortality was 27.5% in adult patients with sepsis who were admitted to hospitals through emergency departments in Korea.

▪Patients with sepsis were more commonly referred to step-down facilities rather than discharged to home, even after acute sepsis care.
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###### 

Baseline characteristics of patients with sepsis who were admitted to hospitals through emergency departments in Korea

  Variable                           Overall (n=977)        Sepsis (n=620)         Septic shock (n=357)   P-value
  ---------------------------------- ---------------------- ---------------------- ---------------------- ---------
  Age (yr)                           75 (64--81)            75 (65--82)            73 (63--80)            0.017
  Male sex                           559 (57.2)             348 (56.1)             211 (59.1)             0.366
  Body mass index (kg/m^2^)          22.3 (19.7--24.6)      22.2 (19.3--24.9)      22.4 (20.0--24.3)      0.961
  Comorbidity                                                                                             
   Diabetes                          284 (29.1)             168 (27.1)             116 (32.5)             0.074
   Cardiovascular disease            270 (27.6)             160 (25.8)             110 (30.8)             0.092
   Chronic neurological disease      213 (21.8)             136 (21.9)             77 (21.6)              0.894
   Chronic lung disease              172 (17.6)             122 (19.7)             50 (14.0)              0.025
   Chronic liver disease             107 (11.0)             65 (10.5)              42 (11.8)              0.537
   Chronic kidney disease            162 (16.6)             105 (17.0)             57 (16.0)              0.679
   Connective tissue disease         24 (2.5)               16 (2.6)               8 (2.2)                0.741
   Solid malignant tumors            258 (26.4)             160 (25.8)             98 (27.5)              0.574
   Hematological malignancies        56 (5.7)               36 (5.8)               20 (5.6)               0.895
   Immunocompromised                 43 (4.4)               24 (3.9)               19 (5.3)               0.287
   Charlson comorbidity index        5 (4--7)               5 (4--7)               5 (4--8)               0.218
  SOFA score                         5 (3--7)               4 (3--6)               8 (5--10)              \<0.001
   Respiration                       2 (1--2)               2 (1--2)               2 (1--3)               0.006
   Coagulation                       0 (0--1)               0 (0--1)               0 (0--2)               0.001
   Liver                             0 (0--1)               0 (0--1)               0 (0--1)               0.030
   Cardiovascular                    0 (0--1)               0 (0--1)               2 (0--3)               \<0.001
   Central nervous system            0 (0--2)               0 (0--1)               0 (0--3)               \<0.001
   Renal                             1 (0--2)               0 (0--1)               1 (0--2)               \<0.001
  Vital sign                                                                                              
   Systolic blood pressure (mmHg)    110 (89--137)          120 (100--141)         90 (75--113)           \<0.001
   Diastolic blood pressure (mmHg)   65 (52--80)            70 (60--84)            54 (43--68)            \<0.001
   Mean blood pressure (mmHg)        80 (65--99)            87 (73--105)           67 (54--83)            \<0.001
   Heart rate (/min)                 104 (89--120)          102 (88--118)          108 (90--122)          0.043
   Temperature (ºC)                  37.2 (36.5--38.2)      37.3 (36.6--38.2)      37.1 (36.4--38.0)      0.004
  Laboratoryfinding                                                                                       
   Lactate (mmol/L)                  2.4 (1.5--4.1)         1.70 (1.20--2.67)      3.90 (2.50--6.26)      \<0.001
   White blood cell (10^3^/L)        11.1 (6.8--16.5)       11.2 (7.3--16.2)       10.9 (5.5--17.0)       0.298
   Hemoglobin (g/dl)                 11.2 (9.7--13.0)       11.4 (9.9--13.0)       11.0 (9.2--12.7)       0.003
   Platelet count (10^3^/L)          178 (108--257)         185 (118--266)         150 (96--237)          \<0.001
   Sodium (mmol/L)                   136 (132--140)         136 (132--139)         136 (132--140)         0.746
   Potassium (mmol/L)                4.3 (3.7--4.7)         4.3 (3.8--4.7)         4.3 (3.6--4.8)         0.305
   Chloride (mmol/L)                 101 (97--106)          101 (97--106)          101 (97--106)          0.892
   Blood urea nitrogen (mg/dl)       26.6 (17.1--44.0)      25 (16--39)            31 (20--55)            \<0.001
   Creatinine (mg/dl)                1.30 (0.85--2.26)      1.18 (0.79--1.98)      1.61 (1.05--2.63)      \<0.001
   AST (U/L)                         36 (24--67)            33 (23--58)            41 (26--90)            \<0.001
   ALT (U/L)                         22 (14--44)            21 (13--41)            24 (15--49)            0.002
   Albumin (g/dl)                    3.0 (2.7--3.5)         3.1 (2.8--3.6)         2.9 (2.5--3.3)         \<0.001
   Prothrombin time (INR)            1.20 (1.08--1.38)      1.17 (1.06--1.29)      1.27 (1.13--1.52)      \<0.001
   C-reactive protein (mg/dl)        12.0 (5.6--23.3)       10.8 (5.1--20.8)       15.0 (6.1--27.9)       \<0.001
   Procalcitonin (mmol/L)            2.36 (0.47--13.17)     1.23 (0.32--5.86)      6.69 (1.22--36.28)     \<0.001
   pH                                7.42 (7.35--7.47)      7.43 (7.37--7.47)      7.39 (7.29--7.46)      \<0.001
   PaCO~2~ (mmHg)                    32.5 (27.0--39.8)      33.8 (28.5--40.3)      30.3 (25.0--38.0)      \<0.001
   PaO~2~ (mmHg)                     70.4 (57.1--88.9)      67.2 (56.3--85.0)      76.2 (58.4--96.9)      \<0.001
   Bicarbonate (mmol/L)              20.8 (17.2--24.4)      22.1 (19.0--25.5)      18.5 (14.3--22.3)      \<0.001
   Troponin (ng/ml)                  0.040 (0.012--0.106)   0.030 (0.010--0.081)   0.056 (0.020--0.171)   \<0.001
   BNP (pg/ml)                       262 (101--770)         231 (98--659)          339 (128--971)         0.044

Values are presented as median (interquartile range) or number (%).

SOFA: Sequential Organ Failure Assessment; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; PaCO~2~: partial pressure of carbon dioxide in arterial blood; PaO~2~: partial pressure of oxygen in arterial blood; BNP: brain natriuretic peptide.

###### 

Characteristics of infection in patients with sepsis who were admitted to hospitals through emergency departments in Korea

  Variable                                                            Overall (n=977)   Sepsis (n=620)   Septic shock (n=357)   P-value
  ------------------------------------------------------------------- ----------------- ---------------- ---------------------- ---------
  Classification of infection                                                                                                   
   Microbiologically documented infection                             444 (45.5)        258 (41.6)       186 (52.1)             0.002
   Clinically documented infection                                    430 (44.0)        293 (47.3)       137 (38.4)             0.007
   Possible infection                                                 103 (10.5)        69 (11.1)        34 (9.5)               0.431
  Site of infection                                                                                                             
   Respiratory tract                                                  604 (61.8)        411 (66.3)       193 (54.1)             \<0.001
   Abdominal cavity                                                   161 (16.5)        83 (13.4)        78 (21.9)              \<0.001
   Urinary tract                                                      122 (12.5)        85 (13.7)        37 (10.4)              0.128
   Skin/soft tissue                                                   27 (2.8)          17 (2.7)         10 (2.8)               0.957
   Catheter-related                                                   7 (0.7)           3 (0.5)          4 (1.1)                0.266
   Neurological                                                       7 (0.7)           5 (0.8)          2 (0.6)                \>0.999
   Infections without a clear primary site of infection               49 (5.0)          16 (2.6)         33 (9.2)               \<0.001
  Type of infection                                                                                                             0.338
   Community-acquired infection                                       790 (80.9)        507 (81.8)       283 (79.3)             
   Hospital-acquired infection                                        187 (19.1)        113 (18.2)       74 (20.7)              
  Cultured pathogen^[a](#tfn1-acc-2019-00514){ref-type="table-fn"}^                                                             
   Respiratory                                                        147 (33.4)        93 (37.7)        52 (27.2)              0.021
   Blood                                                              186 (42.3)        87 (35.2)        104 (54.5)             \<0.001
   Urine                                                              66 (15.0)         48 (19.4)        18 (9.4)               0.004
   Catheter                                                           2 (0.5)           0                2 (1.1)                0.190
   Others                                                             34 (7.7)          19 (7.7)         15 (7.9)               0.950
  Multi-drug resistance pathogen                                      171 (17.8)        96 (15.8)        75 (21.1)              0.039
   *Staphylococcus aureus*                                            36 (21.1)         17 (17.7)        19 (25.3)              
   *Enterococcus species*                                             13 (7.6)          6 (6.3)          7 (9.3)                
   *Enterobacteriaceae*                                               86 (50.3)         52 (54.2)        34 (45.3)              
   *Pseudomonas aeruginosa*                                           18 (10.5)         15 (15.6)        3 (4.0)                
   *Acinetobacter species*                                            9 (5.3)           2 (2.1)          7 (9.3)                
   *Clostridium perfringens*                                          1 (0.6)           0                1 (1.3)                
   No data                                                            8 (4.7)           4 (4.2)          4 (5.3)                

Values are presented as number (%).

Data were available for 438 patients (247 patients with sepsis and 191 patients with septic shock).

###### 

Characteristics of treatments for sepsis

  Variable                                                                                    Overall (n=977)   Sepsis (n=620)   Septic shock (n=357)   P-value
  ------------------------------------------------------------------------------------------- ----------------- ---------------- ---------------------- ---------
  Initial empirical antibiotics                                                                                                                         
   Beta-lactam                                                                                837 (87.5)        534 (88.7)       303 (85.4)             0.130
   Fluroquinolone                                                                             295 (30.8)        189 (31.4)       106 (29.9)             0.619
   Aminoglycoside                                                                             12 (1.3)          7 (1.2)          5 (1.4)                0.769
   Glycopeptide                                                                               86 (9.0)          38 (6.3)         48 (13.5)              \<0.001
   Colistin                                                                                   1 (0.1)           0                1 (0.3)                0.371
   Carbapenem                                                                                 73 (7.6)          27 (4.5)         46 (13.0)              \<0.001
   Macrolide                                                                                  96 (10.0)         75 (12.5)        21 (5.9)               0.001
   Others                                                                                     75 (15.2)         35 (11.2)        40 (22.9)              0.001
   Combination antibiotic therapy                                                             484 (50.5)        293 (48.5)       191 (53.8)             0.113
  Appropriateness of initial antibiotics                                                                                                                
   Appropriate                                                                                670 (68.6)        420 (67.9)       250 (70.0)             0.480
   Inappropriate                                                                              172 (17.6)        103 (16.6)       69 (19.3)              0.288
   Not available                                                                              134 (13.7)        96 (15.5)        38 (10.6)              0.033
  Nonsurgical source control measure implemented                                              132 (13.5)        71 (11.5)        61 (17.1)              0.013
   Removal of infected intravascular or other catheters                                       35 (4.2)          11 (2.1)         24 (7.7)               \<0.001
   Insertion of percutaneous drain catheters                                                  86 (10.3)         49 (9.3)         37 (11.9)              0.227
    Pleural                                                                                   33 (38.4)         16 (32.7)        17 (46.0)              
    Hepatobiliary                                                                             29 (33.7)         18 (36.7)        11 (29.7)              
    Peritoneum                                                                                10 (11.6)         6 (12.2)         4 (10.8)               
    Others                                                                                    14 (16.3)         9 (18.4)         5 (13.5)               
   Other nonsurgical source control measure                                                   20 (2.4)          16 (3.0)         4 (1.3)                0.109
  Surgical source control                                                                     20 (2.1)          9 (1.5)          11 (3.2)               0.075
  Intensive care unit admission                                                               294 (33.9)        111 (20.6)       183 (55.5)             \<0.001
  Treatment during intensive care unit stay^[a](#tfn2-acc-2019-00514){ref-type="table-fn"}^                                                             
   Mechanical ventilation                                                                     182 (63.9)        68 (58.6)        114 (67.5)             0.127
   Renal replacement therapy                                                                  70 (24.6)         25 (21.6)        45 (26.6)              0.328
   Extracorporeal membrane oxygenation                                                        12 (4.2)          5 (4.3)          7 (4.1)                \>0.999
   Hemoperfusion                                                                              22 (7.7)          4 (3.5)          18 (10.7)              0.025

Values are presented as number (%).

Data were available for 286 patients (116 patients with sepsis and 170 patients with septic shock).

###### 

Comparison of survivors and non-survivors

  Variable                                                Survivor (n=703)       Non-survivor (n=267)   P-value
  ------------------------------------------------------- ---------------------- ---------------------- ---------
  Age (yr)                                                74 (63--81)            75 (67--82)            0.049
  Male sex                                                404 (57.5)             152 (56.9)             0.879
  Body mass index (kg/m^2^)                               22.3 (19.8--24.9)      22.2 (19.5--24.2)      0.185
  Comorbidity                                                                                           
   Diabetes                                               207 (29.5)             71 (26.6)              0.380
   Cardiovascular disease                                 187 (26.6)             78 (29.2)              0.415
   Chronic neurological disease                           155 (22.1)             57 (21.4)              0.814
   Chronic lung disease                                   126 (17.9)             45 (16.9)              0.696
   Chronic liver disease                                  81 (11.5)              25 (9.4)               0.336
   Chronic kidney disease                                 120 (17.1)             40 (15.0)              0.442
   Connective tissue disease                              17 (2.4)               7 (2.6)                0.855
   Solid malignant tumor                                  173 (24.6)             84 (31.5)              0.031
   Hematological malignancy                               41 (5.8)               15 (5.6)               0.898
   Immunocompromised                                      30 (4.3)               13 (4.9)               0.684
   Charlson comorbidity index                             5 (4--7)               6 (4--8)               0.085
  SOFA score                                              4 (3--7)               6 (4--10)              \<0.001
  Vital sign                                                                                            
   Systolic blood pressure (mmHg)                         110 (90--140)          104 (84--129)          0.005
   Diastolic blood pressure (mmHg)                        67 (54--81)            60 (50--77)            0.004
   Mean blood pressure (mmHg)                             83 (67--101)           77 (62--93)            0.007
   Heart rate (/min)                                      104 (88--119)          106 (90--122)          0.148
   Temperature (°C)                                       37.5 (36.6--38.4)      36.9 (36.3--37.7)      \<0.001
  Laboratoryfinding                                                                                     
   Lactate (mmol/L)                                       2.2 (1.3--3.5)         3.3 (1.9--6.0)         \<0.001
   Hemoglobin (g/dl)                                      11.4 (9.8--13.0)       10.8 (9.1--12.8)       0.002
   Platelet count (10^3^/L)                               179 (112--263)         170 (98--250)          0.073
   Blood urea nitrogen (mg/dl)                            24 (16--37)            37 (21--59)            \<0.001
   Creatinine (mg/dl)                                     1.23 (0.81--2.03)      1.63 (0.92--2.63)      \<0.001
   AST (U/L)                                              34 (23--59)            44 (26--91)            \<0.001
   ALT (U/L)                                              22 (14--43)            24 (16--48)            0.197
   Albumin (g/dl)                                         3.1 (2.8--3.6)         2.8 (2.3--3.2)         \<0.001
   Prothrombin time (INR)                                 1.17 (1.06--1.32)      1.29 (1.16--1.58)      \<0.001
   C-reactive protein (mg/dl)                             10.9 (4.9--21.9)       15.9 (6.7--27.9)       \<0.001
   Procalcitonin (mmol/L)                                 1.85 (0.39--10.95)     4.93 (0.87--20.49)     \<0.001
   pH                                                     7.42 (7.37--7.47)      7.39 (7.28--7.47)      \<0.001
   PaCO~2~ (mmHg)                                         33.2 (27.8--39.7)      31.8 (25.0--39.8)      0.076
   PaO~2~ (mmHg)                                          70.0 (57.5--88.3)      72.3 (56.0--93.0)      0.736
   Bicarbonate (mmol/L)                                   21.3 (18.0--24.6)      19.5 (14.6--23.2)      \<0.001
   Troponin (ng/ml)                                       0.034 (0.010--0.096)   0.051 (0.020--0.180)   \<0.001
   BNP (pg/ml)                                            222 (89--592)          352 (142--1,445)       0.002
  Site of infection                                                                                     0.003
   Respiratory tract                                      412 (58.6)             189 (70.8)             
   Abdominal cavity                                       117 (16.6)             42 (15.7)              
   Urinary tract                                          104 (14.8)             16 (6.0)               
   Skin/soft tissue                                       21 (3.0)               6 (2.3)                
   Catheter-related                                       6 (0.9)                1 (0.4)                
   Neurological                                           6 (0.9)                1 (0.4)                
   Infections without a clear primary site of infection   37 (5.3)               12 (4.5)               
  Type of infection                                                                                     0.971
   Community-acquired infection                           568 (80.8)             216 (80.9)             
   Hospital-acquired infection                            135 (19.2)             51 (19.1)              
  Multi-drug resistance pathogen                          118 (17.1)             50 (19.1)              0.462
  Appropriateness of initial antibiotics                                                                0.775
   Appropriate                                            486 (69.1)             181 (67.8)             
   Inappropriate                                          123 (17.5)             45 (16.9)              
   Not available                                          93 (13.2)              41 (15.4)              
  Nonsurgical source control measure implemented          102 (14.5)             30 (11.2)              0.182
   Removal of infected intravascular or other catheters   27 (4.5)               8 (3.5)                0.505
   Insertion of percutaneous drain catheters              68 (11.3)              18 (7.8)               0.135
    Pleural                                               25 (36.8)              8 (44.4)               
    Hepatobiliary                                         26 (38.2)              3 (16.7)               
    Peritoneum                                            6 (8.8)                4 (22.2)               
    Others                                                11 (16.2)              3 (16.7)               
   Other nonsurgical source control measure               18 (3.0)               2 (1.9)                0.071
  Surgical source control                                 15 (2.2)               5 (2.0)                0.824
  1-Hour bundle                                                                                         
   Measure lactate level                                  551 (78.6)             230 (86.1)             0.008
   Obtain blood cultures                                  643 (91.7)             245 (91.8)             0.986
   Broad spectrum antibiotics                             472 (67.7)             203 (76.3)             0.009
   Crystalloid fluid                                      243 (34.7)             136 (50.9)             \<0.001
   Apply vasopressors                                     205 (29.4)             133 (49.8)             \<0.001
   Remeasure lactate                                      191 (63.3)             117 (68.0)             0.294

Values are presented as median (interquartile range) or number (%).

SOFA: Sequential Organ Failure Assessment; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; PaCO~2~: partial pressure of carbon dioxide in arterial blood; PaO~2~: partial pressure of oxygen in arterial blood; BNP: brain natriuretic peptide.

###### 

Multivariable logistic regression analysis for probability of hospital mortality in patients with sepsis who were admitted to hospitals through emergency departments in Korea

                                                                      Univariable          Multivariable                       
  ------------------------------------------------------------------- -------------------- --------------- ------------------- ---------
  Age (yr)                                                            1.01 (1.00--1.02)    0.061           1.02 (1.01--1.03)   0.004
  Initial SOFA score                                                  1.17 (1.13--1.22)    \<0.001         1.14 (1.08--1.19)   \<0.001
  Septic shock                                                        3.35 (2.50--4.49)    \<0.001         2.56 (1.80--3.62)   \<0.001
  Solid or hematological malignancy                                   1.34 (1.00--1.80)    0.054           1.84 (1.31--2.58)   \<0.001
  Site of infection^[a](#tfn3-acc-2019-00514){ref-type="table-fn"}^                                                            
   Abdominal                                                          0.78 (0.53--1.16)    0.221           0.66 (0.43--1.02)   0.060
   Urinary                                                            0.34 (0.19--0.58)    \<0.001         0.30 (0.17--0.54)   \<0.001
   Others^[b](#tfn4-acc-2019-00514){ref-type="table-fn"}^             0.62 (0.37--1.05)    0.078           0.37 (0.20--0.67)   0.001
  Measure lactate level                                               1.69 (1.14--2.50)    0.008           1.11 (0.72--1.71)   0.649
  Obtain blood cultures                                               1.00 (0.6.0--1.68)   0.986           0.89 (0.50--1.57)   0.677
  Broad spectrum antibiotics                                          1.54 (1.11--2.12)    0.009           1.17 (0.81--1.69)   0.413
  Crystalloid fluid                                                   1.95 (1.47--2.60)    \<0.001         1.02 (0.71--1.46)   0.905

OR: odds ratio; CI: confidence interval; SOFA: Sequential Organ Failure Assessment.

The reference group is pulmonary infection;

Others include skin/soft tissue, catheter-related, neurological, and systemic infections refer to infections without a clear primary site of infection.

###### 

Clinical outcomes of patients with sepsis who were admitted to hospitals through emergency departments in Korea

  Variable                                                                             Overall (n=977)   Sepsis (n=620)   Septic shock (n=357)   P-value
  ------------------------------------------------------------------------------------ ----------------- ---------------- ---------------------- ---------
  Hospital mortality                                                                   267 (27.5)        114 (18.5)       153 (43.2)             \<0.001
  Discharge destination                                                                                                                          
   Home                                                                                432 (61.5)        328 (65.3)       104 (51.7)             0.001
   Transfer                                                                            271 (38.6)        174 (34.7)       97 (48.3)              0.002
    Step-down referral                                                                 227 (83.8)        146 (83.9)       81 (83.5)              
    Step-up referral                                                                   18 (6.6)          6 (3.5)          12 (12.4)              
    Unknown                                                                            26 (9.6)          22 (12.6)        4 (4.1)                
  Hospital length of stay (day)                                                        9 (3--19)         10 (4--19)       8 (2--19)              0.013
  Limitation of life--sustaining treatments at any time during the current admission   330 (33.9)        146 (23.6)       184 (52.0)             \<0.001

Values are presented as number (%) or median (interquartile range).

[^1]: Current affiliation: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea
